Pfizer, a major pharmaceutical company, offers a high 7.1% dividend yield but has a history of cutting dividends. Investors may find better value in Merck, a competitor with a slightly lower yield. Both companies focus on drug development and have strong research teams. Pfizer’s dividend cut during the Great Recession raises concerns, while Merck has maintained a consistent dividend growth. Most investors may prefer the stability offered by Merck over Pfizer. Analysts recommend exploring other stock options instead of investing $1,000 in Pfizer at this time. The Motley Fool’s top 10 stock picks have historically delivered significant returns.
Read more at Nasdaq: Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?